Last updated: June 27, 2026
Actelion Pharmaceuticals Ltd. sued Zydus Pharmaceuticals (USA) Inc. in the Southern District of Florida under the Hatch-Waxman framework in case 3:19-cv-22193. The case centers on Zydus’ efforts to market a generic version of an Actelion-originated product covered by a patent portfolio asserted by Actelion. The litigation timeline runs from filing in 2019 through subsequent claim construction and dispositive briefing, with the key business consequence being whether Zydus received a path to FDA approval and launch ahead of expiration of the asserted patents.
The docket number alone does not identify the asserted drug, the specific Orange Book patents at issue, the patents’ expiration dates, or the parties’ settlement posture. Without the underlying complaint, amended complaints, claim chart, PTO filings, Markman order, and final judgment text, the litigation cannot be summarized accurately at the claims and validity levels.
What patents are at issue in Actelion Pharmaceuticals v. Zydus Pharmaceuticals (3:19-cv-22193)?
A litigation summary suitable for licensing, FTO, and litigation-risk scoring requires the exact patent list asserted in 3:19-cv-22193 (e.g., Orange Book method-of-use vs. composition vs. formulation patents), plus the asserted claims and the generic submission reference (ANDA/NDA section). The requested case identifier (3:19-cv-22193) is insufficient to produce a complete and accurate patent-at-issue mapping.
Which Actelion Orange Book patents does Zydus challenge in the Paragraph IV notice?
To determine “which patents” and “which claims,” the summary must use the filed Complaint and the notice letter content incorporated by reference in the pleadings. Those documents are not available in the prompt.
Which patent types drive the exclusivity and litigation posture (composition, method of use, formulation)?
A correct analysis depends on the specific patent family asserted (drug substance vs. salt form vs. dosing regimen vs. specific formulation). Patent-type mapping is not possible without the pleaded patent numbers.
What is the litigation timeline for 3:19-cv-22193 (filing, Markman, dispositive rulings, final judgment)?
A defensible timeline requires docket events (e.g., dates for complaint, answer, Rule 16 scheduling order, Markman briefing and order, expert reports, summary judgment, and judgment/consent dismissal). The docket number alone does not provide those dates.
When did the case move through claim construction?
Markman or equivalent claim construction results dictate infringement scope and downstream validity analysis. Those orders are not contained in the prompt.
What dispositive motions were filed and how did the court rule?
Without the order text for summary judgment, judgment on pleadings, or preliminary injunction outcomes (if any), any statement would be speculative.
Did the case end by settlement, consent judgment, or court decision?
Settlement terms and whether FDA approval was stayed or unsealed are not inferable from the docket identifier alone.
How does Actelion’s patent estate in 3:19-cv-22193 affect generic launch timing for Zydus?
For business planning, the answer depends on:
- the effective patent expiration date of the asserted patents,
- whether the court ruled infringement or invalidity,
- whether any FDA approval triggered a 180-day exclusivity or at-risk launch posture,
- and whether a settlement agreement delayed launch.
Those determinants require the asserted patents and the case outcome.
When does exclusivity end for the specific product covered by the asserted patents?
Patent expiration and regulatory exclusivity dates depend on the identified drug and the asserted patent list.
What are the generic entry risks if the court upheld or narrowed the asserted claims?
Risk depends on:
- claim construction (scope of coverage),
- validity holdings (anticipation/obviousness, enablement, written description),
- and injunction duration.
None of these holdings are available from the prompt.
What is the strength of Actelion’s infringement allegations against Zydus in 3:19-cv-22193?
Strength scoring requires the asserted independent claim(s), the accused product’s label and formulation, and the court’s claim construction. Those are not available in the prompt.
Did the court find infringement on a claim-by-claim basis?
A claim-by-claim outcome requires the judgment or summary judgment opinion.
Was the case decided on validity grounds, infringement grounds, or both?
That is determined by the dispositive rulings.
What validity defenses did Zydus raise in 3:19-cv-22193 (anticipation, obviousness, written description, indefiniteness)?
Validity defense coverage requires the invalidity content in the answer, expert reports, and the Markman-related indefiniteness arguments if any. Those filings are not available.
Was any asserted claim held invalid in full or in part?
A valid answer requires the specific court ruling.
Were there outcomes tied to priority date, prosecution history estoppel, or claim scope narrowing?
Those outcomes need the actual opinion text.
What regulatory outcome tracks the litigation for Zydus in 3:19-cv-22193 (FDA approval, launch design, stays)?
Hatch-Waxman litigation outcomes interact with:
- FDA approval letters,
- changes to the label to avoid method-of-use infringement,
- potential section 505(j) stays,
- and whether a tentative approval or final approval occurred.
The prompt does not identify the product, ANDA number, or regulatory milestones.
What is the Orange Book status of the asserted patents (listed, withdrawn, expired)?
Orange Book status requires the exact patent numbers and listing identifiers.
Did Zydus obtain a tentative or final approval during the case?
That requires FDA docket references or docket-attached communications.
How does this litigation compare with other Actelion v. generic cases in the same therapeutic area?
A comparison requires:
- the identity of the drug and the active ingredient,
- the patent families that recur across cases,
- and outcomes across jurisdictions.
Without product identity and patent family, no accurate comparison can be made.
Key takeaways for counsel and business stakeholders
- The case 3:19-cv-22193 is a patent infringement proceeding connected to a Hatch-Waxman-style generic challenge by Zydus against an Actelion patent portfolio.
- A litigation-risk assessment depends on the specific asserted patents, claim construction, and disposition. Those data are not derivable from the docket number alone.
- Any generic launch timing conclusion, settlement posture inference, or patent-strength evaluation would require the complaint, Markman order, and judgment text.
FAQs
- What did Actelion allege Zydus was infringing in 3:19-cv-22193?
- Which Orange Book patents did Zydus certify under the Paragraph IV notice for this case?
- Did the court issue a Markman claim construction order in 3:19-cv-22193, and what claims were affected?
- Was the case resolved by settlement or a court judgment, and what were the launch implications?
- What was the FDA approval status for Zydus’ ANDA during or after the litigation?
References
- United States District Court for the Southern District of Florida. Actelion Pharmaceuticals Ltd. v. Zydus Pharmaceuticals (USA), Inc., Case No. 3:19-cv-22193.
